UNICA IRIS Institutional Research Information System

FRAU, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 78.882
NA - Nord America 2.987
AS - Asia 1.091
SA - Sud America 135
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 83.128
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 78.140
US - Stati Uniti d'America 2.962
CN - Cina 480
SG - Singapore 441
UA - Ucraina 256
SE - Svezia 192
BR - Brasile 114
DE - Germania 79
GB - Regno Unito 69
FI - Finlandia 63
VN - Vietnam 53
KR - Corea 32
IN - India 25
FR - Francia 21
CA - Canada 18
RU - Federazione Russa 15
HK - Hong Kong 12
BD - Bangladesh 10
PL - Polonia 10
BE - Belgio 9
IQ - Iraq 8
NL - Olanda 8
ZA - Sudafrica 8
CZ - Repubblica Ceca 7
AR - Argentina 6
EC - Ecuador 6
EU - Europa 6
JP - Giappone 6
EG - Egitto 5
IR - Iran 5
KE - Kenya 4
MX - Messico 4
BO - Bolivia 3
LT - Lituania 3
MA - Marocco 3
RO - Romania 3
TR - Turchia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
CL - Cile 2
CO - Colombia 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
CH - Svizzera 1
DZ - Algeria 1
ES - Italia 1
GA - Gabon 1
GR - Grecia 1
HR - Croazia 1
ID - Indonesia 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
SA - Arabia Saudita 1
SV - El Salvador 1
TN - Tunisia 1
Totale 83.128
Salva come PNG Salva come JPEG
Città #
Cagliari 76.917
Uta 1.071
Woodbridge 294
Fairfield 287
Chandler 264
Ashburn 257
Singapore 198
Ann Arbor 143
Jacksonville 137
Nyköping 136
Houston 131
Seattle 124
Boardman 117
Wilmington 117
Dallas 101
Dearborn 101
Cambridge 97
Beijing 91
New York 73
Los Angeles 59
Santa Clara 46
Nanjing 40
Shanghai 34
Hefei 32
Boston 31
Seoul 29
Helsinki 24
Buffalo 21
Guangzhou 21
Milan 20
Shenyang 20
Redwood City 19
San Diego 18
Dong Ket 16
Jinan 14
Hebei 13
Ho Chi Minh City 13
Norwalk 12
Jiaxing 11
Council Bluffs 10
Hong Kong 10
Mountain View 10
Munich 10
Toronto 10
Brussels 9
Changsha 9
Nanchang 9
Redondo Beach 9
The Dalles 9
London 8
Orange 8
Chicago 7
Düsseldorf 7
Phoenix 7
Verona 7
Brooklyn 6
Hanoi 6
Ningbo 6
Oristano 6
Padova 6
São Paulo 6
Tianjin 6
Warsaw 6
Wuhan 6
Zhengzhou 6
Atlanta 5
Belo Horizonte 5
Dhaka 5
Frankfurt am Main 5
Hangzhou 5
Modrice 5
Pune 5
Rome 5
San Jose 5
Baghdad 4
Chengdu 4
Gurgaon 4
Kunming 4
Montreal 4
Portsmouth 4
Rio de Janeiro 4
Sassari 4
Stockholm 4
Auburn Hills 3
Baveno 3
Columbus 3
Cracow 3
Durban 3
Jinhua 3
La Paz 3
Mexico City 3
Millbury 3
Monopoli 3
Nairobi 3
Saint Petersburg 3
Salt Lake City 3
San Mateo 3
Sestu 3
Tashkent 3
Tokyo 3
Totale 81.480
Salva come PNG Salva come JPEG
Nome #
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence 3.451
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.226
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.131
Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions 3.076
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 2.978
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2.876
Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: Implications for the study of the affective properties of drugs of abuse 2.807
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2.687
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 2.680
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 2.654
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2.631
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 2.609
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2.597
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 2.502
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.453
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.392
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.204
Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs 2.168
Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain 2.116
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons 2.074
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.060
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.060
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses 1.929
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.923
Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? 1.845
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.844
Effect of adenosine A1 and A2A antagonists on 3,4 methylenedioxymethamphetamine (MDMA)-induced neuroinflammation and dopamine neuron toxicity in mouse brain 1.726
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. 1.668
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.605
Caffeine potentiation of 3,4-methylenedioxymethamphetamine (MDMA) toxicity: role of age 1.597
Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain 1.378
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats 1.254
Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain 1.240
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.139
Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors 1.087
Role of Adenosine A1 and A2A receptors on 3,4-methylendioxymeth-amphetamine (MDMA, Ecstasy)-induced neurotoxicity, astroglia and microglia reactivity in mouse striatum and substantia nigra 981
null 981
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 903
Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs 548
Behavioural correlates of dopaminergic agonists dyskinetic potential in the 6-OHDA lesioned rat 303
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 250
Totale 83.284
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.212
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216.329 0 0 0 0 0 1.682 1.394 875 356 692 741 589
2021/20223.751 333 284 320 195 175 273 388 277 220 327 355 604
2022/20236.193 733 1.043 648 465 559 542 292 340 399 419 526 227
2023/20245.262 280 370 195 305 541 849 831 336 236 374 392 553
2024/20256.979 1.324 1.426 1.166 910 527 563 607 71 116 77 102 90
2025/20261.222 219 117 258 173 251 204 0 0 0 0 0 0
Totale 83.284